Influence of Cochlear Anatomy on Intraoperative Electrically Evoked Compound Action Potentials.

Autor: Fatani, Nawaf¹ (AUTHOR) nawaf.h.fatani@outlook.com, Abdelsamad, Yassin² (AUTHOR), Alsanosi, Abdulrahman¹ (AUTHOR)

Publikováno v: Journal of Clinical Medicine. Aug2024, Vol. 13 Issue 16, p4716. 11p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Autor: Sabado RL; Cancer Institute, New York University School of Medicine, New York.; Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, Harvard Medical School, New York., Pavlick A; Cancer Institute, New York University School of Medicine, New York., Gnjatic S; Ludwig Institute for Cancer Research, Harvard Medical School, New York.; Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, Harvard Medical School, New York., Cruz CM; Cancer Institute, New York University School of Medicine, New York., Vengco I; Cancer Institute, New York University School of Medicine, New York., Hasan F; Cancer Institute, New York University School of Medicine, New York., Spadaccia M; Cancer Institute, New York University School of Medicine, New York., Darvishian F; Department of Pathology, New York University School of Medicine, New York., Chiriboga L; Department of Pathology, New York University School of Medicine, New York., Holman RM; Cancer Institute, New York University School of Medicine, New York., Escalon J; Cancer Institute, New York University School of Medicine, New York., Muren C; Cancer Institute, New York University School of Medicine, New York., Escano C; Cancer Institute, New York University School of Medicine, New York., Yepes E; Cancer Institute, New York University School of Medicine, New York., Sharpe D; Cancer Institute, New York University School of Medicine, New York., Vasilakos JP; 3M Drug Delivery Systems Division, Harvard Medical School, New York., Rolnitzsky L; Cancer Institute, New York University School of Medicine, New York., Goldberg J; Cancer Institute, New York University School of Medicine, New York., Mandeli J; 3M Drug Delivery Systems Division, Harvard Medical School, New York., Adams S; Cancer Institute, New York University School of Medicine, New York., Jungbluth A; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York., Pan L; Ludwig Institute for Cancer Research, Harvard Medical School, New York., Venhaus R; Ludwig Institute for Cancer Research, Harvard Medical School, New York., Ott PA; Cancer Institute, New York University School of Medicine, New York.; Dana-Farber Cancer Institute, Harvard Medical School, New York., Bhardwaj N; Cancer Institute, New York University School of Medicine, New York.; Department of Pathology, New York University School of Medicine, New York.; Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, Harvard Medical School, New York.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2015 Mar; Vol. 3 (3), pp. 278-287. Date of Electronic Publication: 2015 Jan 29.

Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.

Autor: Ott PA; Division of Medical Oncology, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA. Patrick_Ott@DFCI.harvard.edu, Chang J, Madden K, Kannan R, Muren C, Escano C, Cheng X, Shao Y, Mendoza S, Gandhi A, Liebes L, Pavlick AC

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2013 Jan; Vol. 71 (1), pp. 183-91. Date of Electronic Publication: 2012 Oct 12.